Repligen (MIL:1RGEN) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1RGEN Repligen Corp MIL:1RGEN
60 GF Score
Price €154.65
GF Value €151.66
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Repligen Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

MIL:1RGEN
60GF Score
Repligen Corp MIL:1RGEN
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Repligen (MIL:1RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be overvalued. The current stock price of €154.65 is trading 2% above its estimated GF Value™ of €151.66. GuruFocus considers Repligen to be Fairly Valued.

Key valuation signals for MIL:1RGEN:

  • Cash Payments:
  • GF Value™: €151.66 vs. price of €154.65 (2% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the MIL:1RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGEN:USARGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
60GF Score

Get the complete analysis for MIL:1RGEN

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€154.65
Price
€151.66
GF Value